Comparative Pharmacology
Head-to-head clinical analysis: DICUMAROL versus EDOXABAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICUMAROL versus EDOXABAN.
DICUMAROL vs EDOXABAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
60 mg orally once daily
None Documented
None Documented
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
Clinical Note
moderateEdoxaban + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Benzydamine
"Edoxaban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateEdoxaban + Deferasirox
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Category C
Category C
Anticoagulant
Anticoagulant
"The risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox."